Detection of vascular adhesion protein-1 (VAP-1)
OwnerSirpa Jalkanen, Marko Salmiinventors
Life of this patent
Estimating the term…
Abstract
A novel endothelial cell molecule, VAP-1, is described that mediates lymphocyte binding in man. Further described are anti-VAP-1 monoclonal antibodies and methods for the diagnosis and treatment of inflammatory and autoimmune diseases by the administration of VAP-1 binding compounds, such as anti-VAP-1 antibodies.
Claims21
A method for detecting VAP-1 in bodily fluid from a patient, wherein said VAP-1 specifically binds monoclonal antibody 1B2 (DSM ACC2041), comprising:
- (1) removing a sample of the bodily fluid from the patient;
- (2) exposing said sample to a VAP-1-specific antibody;
- and
- (3) detecting VAP-1-specific antibody binding to VAP-1 present in said sample.
A method for diagnosing a medical condition in a patient that is mediated by VAP-1-mediated binding of endothelial cells to lymphocytes, wherein said VAP-1 specifically binds monoclonal antibody 1B2 (DSM ACC2041), said method comprising:
- (1) removing cells from said patient suspected of being VAP-1 positive cells;
- (2) exposing said cells of step (1) to a VAP-1-specific antibody;
- (3) detecting VAP-1-specific antibody binding to said VAP-1 positive cells;
- and
- (4) diagnosing said medical condition on the basis of the amount of said binding.
Dependencies are inferred from the claim text.